Investigation of the use of molecular targeted drugs for ovarian cancer and the impact of companion testing on HBOC treatment in Chugoku and Shikoku regions

Abstract

Synopsis: In this study, we analyzed how the molecular-targeted drugs and related companion diagnosis system were selected in patients newly diagnosis or recurrent ovarian cancer treated at the participating institution in Chugoku and Shikoku region between January 1, 2021 and December 31, 2021.

For newly diagnosed patients, PAOLA-1 regimen (combining maintenance olaparib and bevacizumab) was the most frequently used for HRD (58%), whereas for HRP cases, 55% were treated with bevacizumab and 45% with niraparib. Bevacizumab and niraparib were also used for patients who had not undergone companion diagnosis.

Recurrent cases were divided according to the presence or absence of platinum sensitivity. PARP inhibitors were used in 80% of platinum sensitive relapses, while the majority (78%) of the resistant cases were treated with bevacizumab.

Genetic counseling or testing was performed in 25 of 27 patients with tumor BRCA variant identified by HRD testing. It was revealed that most of the facilities which participated in this research have performed genetic intervention for patients with somatic variant identified by HRD testing, which could be an inducement for HBOC treatment.